Syndax Pharmaceuticals Inc

NASDAQGS:SNDX

Amerika Syarikat / Penjagaan Kesihatan / Bioteknologi

Tinjauan

Dividen

Kewangan Sejarah 10T

Harga Saham

13.18 USD


Key Metrics	Latest
Total Revenue	23.68 M
Adjusted EBITDA	-339.7 M
EBITDA Margin	-1,434.4%
Net Profit Margin	-1,346.1%
Total Assets	724.8 M
Total Debt	345.7 M

10Y Historical Financial Statements

Summary Financials


Summary Financials

	Fiscal Year Ending										Latest
(in millions)	Dec-15	Dec-16	Dec-17	Dec-18	Dec-19	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	12 Months

Revenue	1	1	2	2	2	2	140	0	0	24	24
% Growth		94.6%	72.8%	-28.0%	0.0%	0.0%	9109.6%	-100.0%	NA	NA

Adjusted EBITDA	(20)	(44)	(62)	(76)	(57)	(71)	26	(152)	(230)	(340)	(340)
% Margin	-3268.3%	-3580.1%	-2935.4%	-4996.6%	-3786.9%	-4702.3%	18.8%	NA	NA	-1434.4%	-1434.4%

Adjusted EBIT	(21)	(44)	(62)	(76)	(58)	(71)	26	(152)	(230)	(340)	(340)
% Margin	-3271.6%	-3587.4%	-2939.0%	-5001.7%	-3792.9%	-4708.2%	18.8%	NA	NA	-1434.4%	-1434.4%

Adjusted Net Income	(24)	(44)	(61)	(74)	(56)	(73)	25	(149)	(209)	(319)	(319)
% Margin	-3846.7%	-3645.2%	-2884.3%	-4875.5%	-3694.6%	-4822.5%	17.8%	NA	NA	-1346.1%	-1346.1%

Adjusted Basic EPS	(352.86)	(3.04)	(2.90)	(2.92)	(1.84)	(1.77)	0.48	(2.46)	(2.98)	(3.72)	(3.72)

Menyokong Pengiraan

Income Statement

Balance Sheet

Statement of Cashflows


Income Statement
											Original
USD	Fiscal Year Ending										Latest
(in millions)	Dec-15	Dec-16	Dec-17	Dec-18	Dec-19	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	Dec-24
	FY - 9	FY - 8	FY - 7	FY - 6	FY - 5	FY - 4	FY - 3	FY - 2	FY - 1	FY	LTM

Revenue	1	1	2	2	2	2	140	0	0	24	24
% Growth	NA	94.6%	72.8%	-28.0%	0.0%	0.0%	9109.6%	-100.0%	NA	NA

Cost of Revenue	0	0	0	0	0	0	0	(118)	(163)	(242)	(242)
Gross Profit	1	1	2	2	2	2	140	(118)	(163)	(219)	(219)
% Revenue	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	NA	NA	-924.0%	-924.0%

Research and Development	(10)	(32)	(48)	(60)	(43)	(50)	(88)	(118)	(163)	(242)	(242)
Selling and Marketing	0	0	0	0	0	0	0	0	0	0	0
General and Admin	(12)	(13)	(16)	(17)	(16)	(23)	(25)	(33)	(67)	(121)	(121)
Other Inc / (Exp)	(2)	(2)	(0)	(0)	(0)	(0)	0	118	163	241	241
Total Operating Exp	(23)	(47)	(64)	(77)	(59)	(73)	(113)	(34)	(67)	(121)	(121)

Operating Income	(23)	(45)	(62)	(76)	(58)	(72)	26	(152)	(230)	(340)	(340)
% Revenue	-3621.2%	-3723.6%	-2951.8%	-5003.5%	-3798.2%	-4722.6%	18.9%	NA	NA	-1435.5%	-1435.5%

Interest Expense	(1)	1	1	2	2	(2)	(1)	3	21	21	21
Pre-tax Income	(24)	(44)	(61)	(74)	(56)	(73)	25	(149)	(209)	(319)	(319)
Earnings of Discontinued Ops.	0	0	0	0	0	0	0	0	0	0	0
Provision for Taxes	0	0	0	0	0	0	0	0	0	0	0
Net Income to Company	(24)	(44)	(61)	(74)	(56)	(73)	25	(149)	(209)	(319)	(319)
% Margin	-3846.7%	-3645.2%	-2884.3%	-4875.5%	-3694.6%	-4822.5%	17.8%	NA	NA	-1346.1%	-1346.1%

Minority Interest in Earnings	0	0	0	0	0	0	0	0	0	0	0
Net Income to Stockholders	(24)	(44)	(61)	(74)	(56)	(73)	25	(149)	(209)	(319)	(319)

Preferred Dividends	(10)	(3)	0	0	0	0	0	0	0	0	0
Other Adj.	(70)	0	0	0	0	(4)	0	0	0	0	0

Net Income to Common	(104)	(47)	(61)	(74)	(56)	(77)	25	(149)	(209)	(319)	(319)
% Margin	-16562.2%	-3858.2%	-2884.3%	-4875.5%	-3694.6%	-5080.0%	17.8%	NA	NA	-1346.1%	-1346.1%

As Reported
Basic EPS (Continuing Ops)	(1,519.27)	(3.22)	(2.90)	(2.92)	(1.84)	(1.87)	0.48	(2.46)	(2.98)	(3.72)	(3.72)
Diluted EPS (Continuing Ops)	(1,519.27)	(3.22)	(2.90)	(2.92)	(1.84)	(1.87)	0.46	(2.46)	(2.98)	(3.72)	(3.72)

WA Basic Shares Out.	0.07	14.62	21.00	25.37	30.49	41.31	52.06	60.76	70.37	85.62	85.62
WA Diluted Shares Out.	0.07	14.62	21.00	25.37	30.49	41.31	53.62	60.76	70.37	85.62	85.62

EBITDA, EBIT Reconciliation
EBT, Incl. Unusual Items	(24)	(44)	(61)	(74)	(56)	(73)	25	(149)	(209)	(319)	(319)
Addback: Net Interest Expense	1	(1)	(1)	(2)	(2)	2	1	(3)	(21)	(21)	(21)
Addback: Other Non Operating Expenses, Total	2	2	0	0	0	0	(0)	0	0	0	0
Addback: Depreciation & Amortization	0	0	0	0	0	0	0	0	0	0	0
Addback: Restructuring Charges	0	0	0	0	0	0	0	0	0	0	0
Addback: Merger / Acquisition Expenses	0	0	0	0	0	0	0	0	0	0	0
Addback: Goodwill Impairment	0	0	0	0	0	0	0	0	0	0	0
Addback: Gain (Loss) On Sale Of Invest.	0	0	0	0	0	0	0	0	0	0	0
Addback: Gain (Loss) On Sale Of Assets	0	0	0	0	0	0	0	0	0	0	0
Addback: Asset Writedown	0	0	0	0	0	0	0	0	0	0	0
Addback: In Process R&D Expenses	0	0	0	0	0	0	0	0	0	0	0
Addback: Insurance Settlements	0	0	0	0	0	0	0	0	0	0	0
Addback: Legal Settlements	0	0	0	0	0	0	0	0	0	0	0
Addback: Other Unusual Items	0	0	0	0	0	0	0	0	0	0	0
Adjusted EBITDA	(20)	(44)	(62)	(76)	(57)	(71)	26	(152)	(230)	(340)	(340)
% Margin	-3268.3%	-3580.1%	-2935.4%	-4996.6%	-3786.9%	-4702.3%	18.8%	NA	NA	-1434.4%	-1434.4%

Adjusted EBIT	(21)	(44)	(62)	(76)	(58)	(71)	26	(152)	(230)	(340)	(340)
% Margin	-3271.6%	-3587.4%	-2939.0%	-5001.7%	-3792.9%	-4708.2%	18.8%	NA	NA	-1434.4%	-1434.4%

Adjusted Net Income Reconciliation
Net Income to Company	(24)	(44)	(61)	(74)	(56)	(73)	25	(149)	(209)	(319)	(319)
Addback: Unusual Items	0	0	0	0	0	0	0	0	0	0	0
Less: Tax Benefit of Unusual Items (26%)	0	0	0	0	0	0	0	0	0	0	0
Adjusted Net Income	(24)	(44)	(61)	(74)	(56)	(73)	25	(149)	(209)	(319)	(319)
% Margin	-3846.7%	-3645.2%	-2884.3%	-4875.5%	-3694.6%	-4822.5%	17.8%	NA	NA	-1346.1%	-1346.1%

Hak cipta terpelihara. Terma Penggunaan

Ralat Memuat Turun

Syndax Pharmaceuticals Inc

NASDAQGS:SNDX

Amerika Syarikat / Penjagaan Kesihatan / Bioteknologi

Kewangan Sejarah 10T